Singapore, Oct. 23 -- Prognica Labs, a Dubai-headquartered AI-driven life sciences company, and Pinnacology Research & Development, an India-based pharmaceutical research company, have announced a strategic co-development and commercialisation partnership to advance an investigational intranasal microemulsion therapy for anxiety.

The collaboration aims to translate promising natural-product research into a scientifically validated pharmaceutical development programme, combining Pinnacology's formulation research and technical expertise with Prognica's AI-enabled drug discovery platform, translational R&D capabilities, clinical development intelligence and international commercialisation network.

Anxiety disorders represent one of the wo...